Recognizing September 2025 As "prostate Cancer Awareness Month In The State Of Delaware.
Summary
Senate Concurrent Resolution 75 is a nonbinding legislative resolution that designates September 2025 as "Prostate Cancer Awareness Month" in Delaware. The resolution recites background information about prostate cancer, including its prevalence, risk factors, symptoms, screening recommendations, and the importance of early detection and treatment. It also notes that light blue is the awareness color associated with prostate cancer.
The measure does not create or amend any substantive state law, regulate conduct, or appropriate funds. Instead, it serves as an official state recognition intended to raise public awareness, encourage screening, and support education and research efforts related to prostate cancer. Its practical effect is symbolic and promotional, with the General Assembly formally joining a national awareness effort for the month of September 2025.
The available voting history suggests the resolution was received favorably, with the Senate Third Reading passing 16-0. There is no committee transcript or recorded debate in the provided materials, and no evidence of opposition in the vote history. The lack of dissent is consistent with the resolution’s commemorative and public-health-oriented purpose.
Because the resolution is largely ceremonial, there are few points of contention reflected in the record. Any potential policy discussion would likely center on the public-health messaging itself, such as awareness, screening guidance, and the emphasis on higher-risk populations including older men and African-American men. However, the provided materials do not show any disagreement over those points.
Impact
SCR75 has no direct effect on Delaware statutes, regulations, or agency authority. It does not amend the Delaware Code or impose legal obligations; rather, it formally recognizes September 2025 as Prostate Cancer Awareness Month and may be used by state officials, health organizations, and advocacy groups to promote screening and education efforts. Its impact is therefore symbolic and public-facing, aimed at awareness and outreach rather than legal change.
Sentiment
The sentiment around SCR75 appears strongly positive and unanimous. The resolution passed the Senate Third Reading 16-0, and the bill text frames prostate cancer awareness as a broadly supported public-health goal. With no committee transcript or recorded objections provided, the available record indicates consensus support for the recognition and the awareness campaign it promotes.
Contention
There is little to no visible contention in the provided record because SCR75 is a commemorative resolution rather than a policy bill. The only potentially sensitive issues are the public-health claims and screening recommendations included in the preamble, such as baseline screening at age 40 and the emphasis on higher-risk groups like older men and African-American men. However, no opposition, amendment debate, or disagreement is reflected in the vote history or transcripts provided.